Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2020
Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01)Natalie Y L Ngoi, Valerie Heong, Johann I Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2025
Durvalumab versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): a multicenter, randomized, phase 2 trialNatalie Y L Ngoi, Chel Hun Choi, Junxian Zhu, et al.
Frontiers in Oncology|May 30, 2024
Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unitRobert John Walsh, Rebecca Ong, Seng Wee Cheo, et al.
Targeted Oncology|June 14, 2022
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis InhibitorsJoan R E Choo, Yi-Hua Jan, Samuel G W Ow, et al.
The Lancet. Oncology|January 18, 2026
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trialNatalie Y L Ngoi, Jung-Yun Lee, Diana Lim, et al.
The Lancet Regional Health. Western Pacific|July 23, 2025
Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germline APOBEC3B deletion: results of the phase II AUROR studyGwo Fuang Ho, Soo Chin Lee, Anita Zarina Bustam, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 1, 2024
Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers-an Asian tertiary institution experienceVictor Guan Hui Lee, Jerold Loh, Fu Hui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast CancerJoline S J Lim, Andrea L A Wong, Samuel G W Ow, et al.
Pageof 5